OSE Immunotherapeutics (ISIN:FR0012127173; Mnemo:OSE) has announced positive results from the induction period its Phase 2 study of Lusvertikimab (OSE-127), demonstrating strong efficacy and a favorable safety profile...
Maxim Group initiated coverage of OSE Immunotherapeutics (NXT PA:OSE) with a “buy” rating and $22 price target. The stock closed at $13.56 on June 22. Analyst Naureen Quibria, Ph.D., writes that French-based OSE has a...
H.C. Wainwright raised its price target for OSE Immunotherapeutics (NXT PA:OSE) to €10 from €7, citing strong results in PD-1 refractory non-small cell lung cancer (NSCLC) from the first 100-patient cohort of the Phase...